| coronary artery disease | Coronary Artery Bypass Surgery | not classified | versus no TMR No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Allen, 2000 | TMR+CABG vs CABG | | | | | Loubani, 2003 | TMR+CABG vs CABG | | | | | Zhao, 2006 | TMR+CABG vs CABG | | | |
| Trial | Treatments | Patients | Method |
|---|
| Allen, 2000 | coronary bypass of suitable vessels plus transmyocardial revascularization to areas not graftable (n=132) vs. coronary bypass alone with nongraftable areas left unrevascularized (n=131) | patients whose standard of care was coronary artery bypass grafting and who had one or more ischemic areas not amenable to bypass grafting | single blind Sample size: 132/131 Primary endpoint: FU duration: | | Loubani, 2003 | coronary artery bypass grafting plus transmyocardial laser revascularization with a holmium:YAG (yttrium-aluminum-garnet) laser to nongraftable areas (n=10) vs. coronary artery bypass grafting (n=10) | Patients who had elective coronary artery bypass with one or more nongraftable coronary arteries | open Parallel groups Sample size: 10/10 Primary endpoint: none defined FU duration: 36 months | | Zhao, 2006 | transmyocardial laser revascularization (holmium: YAG) combined with off-pump coronary artery bypass (n=40) vs. off-pump coronary artery bypass (n=40) | patients with diffusely diseased target vessels | open Parallel groups Sample size: 40/40 Primary endpoint: not defined FU duration: 3.4y |
|
